Raynaud’s phenomenon – European Clinical Trials Information Network https://clinicaltrials.eu Bridging Patients with Clinical Trials Fri, 12 Jun 2026 11:19:34 +0000 en-US hourly 1 https://wordpress.org/?v=7.0 https://clinicaltrials.eu/wp-content/uploads/2024/12/cropped-EU_icon-32x32.png Raynaud’s phenomenon – European Clinical Trials Information Network https://clinicaltrials.eu 32 32 Study of Intravenous Sodium Thiosulfate for Treatment of Primary Raynaud’s Phenomenon https://clinicaltrials.eu/trial/study-of-intravenous-sodium-thiosulfate-for-treatment-of-primary-raynauds-phenomenon/ Wed, 29 Apr 2026 15:07:20 +0000 https://clinicaltrials.eu/trial/study-of-intravenous-sodium-thiosulfate-for-treatment-of-primary-raynauds-phenomenon/ This clinical study focuses on people with primary Raynaud’s phenomenon, a condition where blood vessels in the fingers and toes narrow excessively in response to cold temperatures or stress, causing affected areas to turn white and blue and feel numb or painful. The study will test a medication called sodium thiosulfate, given through intravenous administration (directly into a vein) as a solution for infusion.

The purpose of this research is to determine how different doses of sodium thiosulfate affect blood vessel widening in people with Raynaud’s phenomenon. During the study, participants will receive the medication through an infusion into their veins. The maximum daily dose will be 25 grams, and the treatment period will last for one day.

The study will measure how well blood flows through the small blood vessels in participants’ hands using special imaging techniques. Researchers will also monitor the safety of the treatment by checking blood pressure, heart activity, and looking for any unwanted effects. Blood samples will be collected to understand how the medication moves through the body and affects various biological processes.

]]> Study on Clopidogrel’s Effect in Preventing Systemic Sclerosis for Patients with Raynaud’s Phenomenon and Specific Immune Conditions https://clinicaltrials.eu/trial/study-on-clopidogrels-effect-in-preventing-systemic-sclerosis-for-patients-with-raynauds-phenomenon-and-specific-immune-conditions/ Wed, 29 Apr 2026 14:56:59 +0000 https://clinicaltrials.eu/trial/study-on-clopidogrels-effect-in-preventing-systemic-sclerosis-for-patients-with-raynauds-phenomenon-and-specific-immune-conditions/ This clinical trial is focused on studying the effects of the medication Clopidogrel on reducing the risk of developing Systemic Sclerosis in individuals who have specific immune system characteristics and experience Raynaud’s Phenomenon. Raynaud’s Phenomenon is a condition where some areas of the body, like fingers and toes, feel numb and cold in response to cold temperatures or stress. Systemic Sclerosis is a rare disease that involves the hardening and tightening of the skin and connective tissues. The study will compare the effects of Clopidogrel with a placebo to see if it can prevent the onset of Systemic Sclerosis over a period of five years.

Participants in the study will be randomly assigned to receive either Clopidogrel or a placebo. The medication will be taken orally in the form of film-coated tablets. The study will last for up to 24 months, during which participants will be monitored for any signs of Systemic Sclerosis and other related symptoms. The goal is to determine if Clopidogrel can effectively reduce the risk of developing this condition in people who are at higher risk due to their immune system profile and symptoms of Raynaud’s Phenomenon.

Throughout the study, participants will undergo regular check-ups to assess their health and any changes in their condition. The study aims to provide valuable information on whether Clopidogrel can be used as a preventive treatment for Systemic Sclerosis, potentially offering a new approach to managing this challenging disease. Participants’ health and safety will be closely monitored by medical professionals throughout the trial.

]]>